INTRODUCTION Table 1: Patient Characteristics Before and After Propensity Score Matching
• The availability and efficacy of factor replacement therapy result in significant improvements in treatment outcomes for people with hemophilia B, including less frequent bleeding, pain and arthropathy [1] . Improvements in treatment outcomes may also influence patients' social activity and quality of life [2] . • Recent studies suggested that patients with hemophilia B consume yearly less factor IX clotting factor concentrates (CFC) for therapy treatment than patients with hemophilia A [3] . And there is an overall increase in the amount of factor IX CFC used in the treatment of hemophilia B over the past decade [4] . However, few studies focused on the impact of factor consumption on patient-reported health outcomes.
• To describe the consumption of factor IX CFC among a sample of persons with hemophilia B within the United States (US).
• To examine the relationship between health status and factor consumption within this sample from the Hemophilia Utilization Group Study Part Vb (HUGS Vb).
OBJECTIVES Data Source:
• HUGS Vb is a prospective, observational, multi-center cohort study assessing healthcare utilization and burden of illness among persons with hemophilia B in the US. • Data on hemophilia B patients was collected between 2009 and 2013 from 10 Hemophilia Treatment Centers (HTCs) caring for patients across 11 states in the US.
• Collected information included: socio-demographics, disease severity, treatment regimen (prophylaxis or on-demand), frequency of bleeding episodes, and health status/HRQoL. • Data were either self-reported by adult patients or reported by patient-proxies (parents) for children <18 years of age. • Health status was assessed using the utility scores derived from the EQ-5D index and Visual Analogue Scale (VAS) at the initial interview (baseline) and at one-year follow-up (higher scores indicate better health).
• Weekly factor consumption was estimated from one-year factor dispensing records.
Statistical Analysis:
• Based on the observed factor consumption (mean consumption: 48.9±54.7 IU/kg/week), patients were categorized into one of the following two groups: mean factor consumption ≥50 IU/kg/week or mean factor consumption <50 IU/kg/week. • Propensity score matching (PSM) was applied to adjust for potential selection bias between the two factor consumption groups. Age, treatment regimen, and bleeding frequency were included in the propensity score model. • Covariate adjusted (ANCOVA) utility scores were also calculated and the results were compared to those from PSA.
METHODS RESULTS

DISCUSSION
CONCLUSIONS
• A total of 96 patients were included in this study, 36 (38%) received CFC ≥50 IU/kg/week (mean weekly consumption 106.2±46.8 IU/kg, range: 51.1-267.3 IU/kg), and 60 (62%) had mean weekly factor consumption <50 IU/kg (mean weekly consumption 13.0±12.1 IU/kg, range: 0.5-42.4 IU/kg). • Higher factor consumption in hemophilia B patients was significantly associated with younger age, fewer years of education, non-white ethnicity, severe disease, use of prophylactic regimen and a higher bleeding frequency (Table 1 ).
• After applying PSM, age group, race, treatment regimen and bleeding frequency were not statistically significantly different between the two factor consumption groups. However, disease severity and education were still significantly different between the two factor consumption groups. In addition, the most of the variables have standardized difference greater than 10%, which indicated the variables were not matched well (Table 1 ).
• Generally, higher factor consumption was observed among children. Patients on prophylaxis used almost twice as much factor concentrate as those treating episodically (Figure 1 & 2 ). • Overall, the mean adjusted utility scores were similar between PSM and ANCOVA. Lower baseline EQ-5D index scores were generally observed among the ≥50 IU/kg/week consumption group at baseline, while similar EQ-5D index scores were observed in both factor consumption groups at one-year follow-up (Table 2 & 3) .
• This study provides preliminary information on the association between factor consumption and health status. However, several points should be noted: first, factor consumption was abstracted from one-year dispensing records, which likely reflect the actual use of factor by patients; second, the cutoff of factor consumption (50 IU/kg/week) was based on the distribution of annual factor dispensed within a sample comprising of mild, moderate, and severe patients, which may reflect doses lower than that clinically recommended for severe hemophilia patients.
• Because of the mix of patients with prophylaxis and on-demand regimen, it is predictable that those patients with prophylaxis regimen would consume more factor products. It is more difficult to accurately determine factor consumption for patients using on-demand treatment because consumption may vary significantly from week to week. Therefore, annual records for patients using on-demand regimens may be needed to more accurately characterize factor consumption.
• At baseline, differences in utility scores between two factor consumption groups may reflect potential confounders, such as treatment history prior to enrollment in the study, for which we did not collect such data in the current analysis.
• EQ-5D index score reflects a population-based preference, while VAS measures an individual's general perception of patients' health.
• Age, treatment regimen and bleeding frequency were included in the PSM model based on the logistic regression model with stepwise selection procedure. However, only race and treatment regimen have the balance match.
• Among a sample of persons with hemophilia B seen at HTCs in the US, only small differences in health status were found as measured by VAS between two factor consumption subgroups at one-year follow-up.
• The results from PSM and ANCOVA were similar.
• Further studies to assess how treatment patterns (prophylaxis vs. on-demand) impact health status will help to characterize disease impact on the health status of persons with hemophilia B. c Indicates the number of bleeding episodes during the past 12 months; d prophylaxis means to infuse clotting factor concentrates on a regular schedule to prevent bleeds from occurring; on-demand means to infuse factor concentrates as needed to treat active bleeding; e D indicates standardized difference. A standardized difference of less than 10% has been recommended as supporting the assumption of balance between the intervention and the matched control group. Note: percentages indicated column percentages. P values were calculated from Chi-square tests for categorical variables and Kruskal-Wallis test for continuous variables. ISPOR 2014
